GlassScriptPhysician profile
Timothy C Goodson
NPI 1578538252
$147,277.71
in general payments reported to CMS, 2019-2025
38 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $28K · 2021: $27K · 2022: $30K · 2023: $2,955 · 2024: $16K · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,778 · Travel and Lodging: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $6,778.18 |
| Travel and Lodging | $460.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cryo Specialty Medical, LLC | $124,500.00 | 2019-2024 | |
| Astellas Pharma US INC | $3,394.88 | 2019-2024 | Xtandi, Myrbetriq |
| Abbvie INC. | $3,026.90 | 2019-2025 | |
| Pfizer INC. | $2,824.75 | 2019-2025 | |
| Coloplast Corp | $2,685.19 | 2019-2025 | Titan |
| Astellas Pharma Global Development | $1,920.00 | 2022 | |
| Axonics, INC. | $1,268.75 | 2020-2024 | Axonics, Bulkamid |
| Myriad Genetic Laboratories, INC. | $1,135.25 | 2020-2025 | Myrisk, Prolaris, Precisetumor |
| Sumitomo Pharma America, INC. | $939.87 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $794.20 | 2021-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $793.53 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $657.56 | 2019-2025 | Provenge |
| Boston Scientific Corporation | $561.01 | 2020-2025 | Axonics, Rezum Generator |
| Neotract INC. | $365.22 | 2019-2020 | |
| Myovant Sciences INC. | $278.17 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $253.25 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.52 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $210.81 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $168.59 | 2023-2024 | Trelstar |
| Tolmar, INC. | $149.91 | 2023-2025 | Eligard, Jatenzo |
| Medtronic USA, INC. | $140.24 | 2019-2020 | |
| Procept Biorobotics Corporation | $127.49 | 2020-2024 | Aquabeam System, Aquabeam Robotic System |
| Astrazeneca Pharmaceuticals LP | $109.78 | 2021-2024 | Lynparza |
| Allergan, INC. | $104.40 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $101.53 | 2019-2024 | Adstiladrin |
| Antares Pharma, INC. | $97.54 | 2022-2025 | Xyosted |
| Urogen Pharma, INC. | $81.09 | 2021-2025 | |
| Amgen INC. | $62.99 | 2019-2022 | |
| Olympus America INC. | $52.38 | 2025 | Itind System |
| Angiodynamics, INC. | $42.12 | 2023-2024 | Nanoknife |
| Merck Sharp & Dohme LLC | $36.60 | 2022-2024 | Lynparza |
| Urovant Sciences INC | $30.80 | 2021-2022 | |
| Photocure INC | $30.52 | 2022 | |
| Valencia Technologies Corporation | $23.66 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $23.60 | 2019 | |
| Medtronic, INC. | $16.31 | 2021 | |
| Travere Therapeutics, INC. | $14.38 | 2019 | |
| Caris Mpi, INC. | $13.92 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$394,464.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Goodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.